Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Or any progressive news would be welcome. Seem to have gone off the boil abit.
A fundraise at a premium is almost unheard of in the current market, this is a great vote of confidence and I too expect the SP to rise back to 30+ when markets normalise. The key to unlocking further value will be from commercial agreements though
As ever with AIM placings the quality of the participants in the placing will determine how long the churn goes on.
That’s on you, Ali.
A good entry point for new investors or those looking to add.
SP - I think this was walked down from the 40s.
Solid sounding signals from corporate, building their operational side in tact with commercial ventures (although no new ones mentioned).
SP back up to the 40s within 3-4 months is my guess.
100%. The filing for patents means that good news on the testing will follow shortly. I have taken a hit over the last few months but I can see this gathering pace between now and the autumn.
Still holding for the fully-realised potential of this company to blossom.
Which promises to be very significant.
I’m glad that I’m into ETX for the long haul. A 15% spread makes it nearly impossible to trade short term.
The revenues are still pitiful, but they have plenty of cash and some good collaborations
Very pleased. No one-trick pony this one.
Delivering now and very promising for the future. Onwards!
Is she rousing herself after the slumber?
Hopefully a good run up to the 4th of May.
All good.
Some big trades, usually indicates positioning before a steady rise.
Short and sweet.
She didn’t press him on a percentage breakdown of market-ready compounds etx have a role in delivering. He would Not have answered any road up.
More collaborations in the same vein in the near future fingers crossed.
‘We learn more about our platform’ - etx is a commercial entity in need of maturity with an as yet undefined potential.
From the iTeos pipeline homepage:
We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.
We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.
Get the agar plates out, Ali. There's screening to be done!
First reasonable piece of news this year.. and as usual very little to go on. Oh well at least we know they're alive
Finally some news and positive at that.
'Undisclosed milestone payments' as with previous cooperations and more indirect commercial exposure to lucrative therapeutic markets.
Well it looks like it’s found it’s bottom judging by todays rise
Small trade off-loading, constant and draining.
Plenty of small holders like myself that have been in since single digits and harvesting their gains now.
For what it is worth I have not sold.
It's now lost half it's value in 2 months............what's going on?
Just added another 5800. Great opportunity.
Quested may have more than Ali now.
You're right - it's a recurring pattern with them and Richard Grffiths.
He's clearly got a few quid and likes anything that Mortazavi touches. No idea why this company is valued at such a high market cap but I'll carry on holding a few to find out either way..
Then a 3million trade then another over half a mill...and then an RNS saying that Robert Quested has increased his holding.
Any got a take on his holding in SLN and here?
at 32p.
Its taxing and dull at times but I haven't sold a bean.
For Therapeutics.....
https://www.lse.co.uk/news/novartis-buys-uk-gene-therapy-firm-gyroscope-for-up-to-usd15-billion-7hcjsgwazuyrfae.html